Market Place
Sourcing Support
Teva Presents Schizophrenia Research, Phase 3 SOLARIS Trial Results
01 Nov 2024 //
GLOBENEWSWIRE
Teva Presents TEV-`749 Phase 3 Data For Schizophrenia
21 Sep 2024 //
GLOBENEWSWIRE
Medincell’s Partner Teva Updates on Phase 3 of Olanzapine Long-Acting Injectable
05 Sep 2024 //
BUSINESSWIRE
Medincell`s Partner Teva Updates On Olanzapine LAI And UZEDY®
31 Jul 2024 //
BUSINESSWIRE
USPTO Grants Patent For Olanzapine Vomiting/Nausea Treatment
20 May 2024 //
GLOBENEWSWIRE
Teva and MedinCell`s long-acting schizophrenia med wins in phase 3
09 May 2024 //
FIERECE PHARMA
Teva and Medincell: Positive Phase 3 Results for TEV-‘749 in Schizophrenia
08 May 2024 //
BUSINESSWIRE
Alkermes Presents Analyses From Long-Term Safety Study of LYBALV at SIRS
08 Apr 2024 //
PR NEWSWIRE
Teva Announces Recruitment Completion of Phase 3 Clinical Study of Olanzapine
09 Jan 2024 //
BUSINESSWIRE
Alkermes Announces Topline Results From Study of LYBALVI
03 Jan 2024 //
PR NEWSWIRE
Journal of Clinical Psychiatry Publishes Data from Alkermes` Study of LYBALVI
23 Mar 2023 //
PR NEWSWIRE
Zydus receives final approval from the USFDA for Olanzapine
13 Mar 2023 //
INDIANPHARMAPOST
In Situ Co-Amorphization of Olanzapine in the Matrix and on the Coat of Pellets
02 Dec 2022 //
PHARMAEXCIPIENTS
Phase 3 Study to Be Initiated for Injectable Antipsychotic
29 Aug 2022 //
BUSINESSWIRE
Alkermes` Lybalvi a new litmus test for mental illness marketing
24 Feb 2022 //
FIERCEPHARMA
Alkermes Shows Positive Results From ENLIGHTEN-Early Phase 3b Study of LYBALVI
08 Feb 2022 //
PRNEWSWIRE
Enforcement Report - Week of August 18, 2021
18 Aug 2021 //
FDA
Alkermes schizophrenia drug gets U.S. FDA approval
02 Jun 2021 //
REUTERS
FDA Accepts Alkermes` Resubmission of New Drug Application for ALKS 3831
29 Dec 2020 //
PRNEWSWIRE
Hanmi wins suit against Lilly over drug price cut
27 Nov 2020 //
KOREABIOMED
Enforcement Report - Week of November 11, 2020
11 Nov 2020 //
FDA
Alkermes’experts mixed on how October FDA AdCom will assess Phase III data
16 Sep 2020 //
CLINICALTRIALS ARENA
Indoco Remedies gets USFDA nod for schizophrenia, bipolar disorder drug
05 Aug 2020 //
MONEYCONTROL
Indoco Remedies Generic Olanzapine Receives Approval in US
31 Jul 2020 //
FDA
Impel NeuroPharma Announces Publication of Positive Results of SNAP 101
30 Jun 2020 //
PRNEWSWIRE
Impel NeuroPharma Announces Publication of Positive Results of SNAP 101 Study
30 Jun 2020 //
PRNEWSWIRE
Olanzapine may help control nausea, vomiting in patients with advanced cancer
08 May 2020 //
SCIENCEDAILY
Journal of Clinical Psychiatry Publishes Data from Alkermes` Pha3 ALKS 3831
04 Mar 2020 //
PR NEWSWIRE
Troubled Alkermes eyes November OK for new antipsychotic
29 Jan 2020 //
PMLIVE
Sanofi/Regeneron Dupixent; Alkermes` antipsychotic get dates with the FDA
28 Jan 2020 //
ENDPTS
JPM: In conversation with Steve Paul, CEO of Karuna Therapeutics
16 Jan 2020 //
FIERCE BIOTECH
Catalent, Ethicann Partner on Fast-Dissolve Treatment
03 Dec 2019 //
PRESS RELEASE
Cycle, Catalent to Develop Formulations Targeting Rare Disorders
30 Oct 2019 //
CONTRACTPHARMA
Chinese growth shot’s some years away for pharma companies
10 Oct 2019 //
ECONOMIC TIMES
Hansoh grabs $1B windfall in the latest China pharma IPO
08 Jun 2019 //
ENDPTS
Alkermes says long-acting drugs help schizophrenics stay on medication longer
10 Apr 2019 //
REUTERS
Johnson & Johnson`s nasal spray for depression wins FDA panel backing
14 Feb 2019 //
REUTERS
Alkermes Looks To FDA For Approval Of Schizophrenia Drug
07 Dec 2018 //
SEEKING ALPHA
Alkermes Schizophrenia Drug Heads To FDA, But Questions Linger
30 Nov 2018 //
XCONOMY
Alkermes schizophrenia drug keeps weight gain side effect in check
30 Nov 2018 //
REUTERS
Philadelphia crack down on pharma reps with registration, gift banning
29 Nov 2018 //
FIERCE PHARMA
Philadelphia crack down on pharma reps with registration, gift banning
29 Nov 2018 //
FIERCE PHARMA
Sunshine Lake` Generic Olanzapine Receives Approval in US
22 Nov 2018 //
FDA
Jiangsu Hansoh Pharm`s Generic Olanzapine Receives Approval in US
28 Sep 2018 //
FDA
Intranasal antipsychotic Ph I study begins with first participant dosed
08 Sep 2018 //
IN-PHARMATECHNOLOGIST
Zydus Pharms USA Inc.`s Generic Olanzapine Receives Approval In The US
21 Jul 2018 //
FDA
Zydus Cadila gets USFDA nod to market 4 generic products
17 Jul 2018 //
HINDU BUSINESS LINE
HEC Pharm Co Ltd’s Generic Olanzapine Receives Approval In The US
06 Jul 2018 //
FDA
Alkermes to Host Webcast and Conference Call to Discuss ALKS 3831 Deve. Program
09 Jun 2018 //
PRESS RELEASE
US FDA clears Biohaven IND application for sublingual BHV-0223
01 Nov 2017 //
PHARMABIZ
Eli Lilly’s odyssey to use a fake rule and fake news to protect bad patents
17 Aug 2017 //
STAT
Alkermes is advancing `full steam` with schizophrenia drug
01 Jul 2017 //
FIERCE BIOTECH
Hikma Pharm’s Generic Olanzapine Receives Approval In US
20 Jun 2017 //
FDA
Enforcement Report - Week of May 17, 2017
17 May 2017 //
FDA
Dr Reddy`s, Aurobindo recall drugs from US market
16 Feb 2017 //
ECONOMIC TIMES
New FDA Report Cites 22 Drugs That Passed PhII But Crashed and Burned in PhIII
21 Jan 2017 //
BIOSPACE
Effect of polymers in moisture sorption & physical stability of olanzapine
15 Dec 2016 //
PHARMA EXCIPIENTS
Bristol-Myers to pay $19.5 million in Abilify off-label marketing settlement
14 Dec 2016 //
FIERCE PHARMA
Ajanta Pharms Generic Olanzapine Approved In US
30 Aug 2016 //
FDA
